Former Moderna leaders raise $325M for biotech venture firm Ascenta Capital
Two former Moderna executives started building a biotech venture firm in 2023, and now that firm, known as Ascenta Capital, has unveiled a $325 million closing of its inaugural fund. ...
View ArticleAviadoBio, UgeneX Therapeutics ink up to $413M deal; Apogee’s $300M stock sale
Plus, news about Regeneron and Phagos: 👁️ AviadoBio gets an option deal for eye gene therapy: The company is partnering with UgeneX Therapeutics on a therapy called UGX-202, with AviadoBio getting ...
View ArticleAstraZeneca breaks ground on Virginia plant after Trump warns drugmakers to...
AstraZeneca is breaking ground on a multibillion-dollar API facility in Albemarle County, VA, making it the latest company to start building after President Donald Trump threatened 100% tariffs on...
View ArticleEvommune files for IPO to fund two Phase 2 autoimmune drugs
Biotech IPOs appear to be making a comeback. Autoimmune biotech Evommune on Thursday became the latest company to flash its IPO plans, filing its prospectus to go public on the New ...
View ArticleAltos Labs is testing anti-aging therapies in organs kept alive outside the body
SEVILLE, SPAIN — Altos Labs has raised billions of dollars and hunted university departments for star researchers to develop therapies that delay or rewind aging. But the four-year-old startup has said...
View ArticleSamsara BioCapital eyes $200M opportunity fund
Samsara BioCapital, an investment firm that has backed dozens of life sciences companies, is aiming to raise up to $200 million for its opportunity fund, according to an SEC filing. ...
View ArticleYpsomed spends $248M to gain its first US manufacturing site
The Swiss company Ypsomed is buying a 15,000-square-meter factory in Holly Springs, NC, as President Donald Trump continues to pressure drugmakers to move manufacturing to the US. The drug delivery...
View ArticleShape's former CSO picks up tech role at Moderna; Lilly reels in Peter Marks
→ Recently departed Shape Therapeutics chief scientific officer David Huss has stepped into the chief technology role for Moderna’s research unit. He had served ...
View ArticleBristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition
Bristol Myers Squibb is delving further into cell therapies with the $1.5 billion cash purchase of Orbital Therapeutics, the New Jersey pharma said Friday morning. The move positions BMS in the ...
View ArticleFrench non-profit bets on Duchenne gene therapy that comes in lower dose than...
Genethon's latest data suggest its Duchenne muscular dystrophy gene therapy helped stabilize functional outcomes after two years. However, the trial enrolled only five patients, who were then compared...
View ArticleSatellos to run a trial for Duchenne pill in kids; Idorsia raises $81M
Plus, news about Quoin and OS Therapies: 🧬 Satellos to test Duchenne pill in kids: The company on Friday reported results in five adult patients who received its experimental Duchenne muscular ...
View ArticleCabaletta Bio says small number of autoimmune patients responded to its CAR-T...
A microcap biotech from Philadelphia released early, but positive findings from its CAR-T trial for a rare autoimmune disorder, suggesting it could be administered without one of the most arduous...
View ArticleBiopharma is wagering billions of dollars that CAR-T therapy can be easier....
Large biopharma companies have spent over $4 billion in 2025 to buy startups working on in vivo CAR-T therapies as the first data in humans emerge. While it's still early days for in vivo cell ...
View ArticleWhite House, AstraZeneca expected to announce drug price deal
The White House and AstraZeneca are expected to announce a deal on drug pricing later Friday, according to people familiar with the matter, as President Donald Trump strikes a second agreement under...
View ArticleJ&J is in discussions to buy out Protagonist Therapeutics — report
Johnson & Johnson is reportedly in talks to acquire a partner that’s developing a linchpin of its future immunology plans. J&J and Protagonist Therapeutics are in discussions for a buyout, the...
View ArticleHead of FDA's orphan drug office is removed from role
The head of the FDA office that helps determine orphan drug designations has been reassigned and is no longer in the role, an administration official confirmed to Endpoints News. Sandra Retzky,...
View ArticleNew study suggests patients with anti-AAV antibodies may still receive gene...
SEVILLE, SPAIN — Gene therapies are offering new hope to some patients with rare disease, but not everyone. A third or more of patients are often turned away because they've already been infected with...
View ArticleAstraZeneca strikes pricing deal with Trump
British pharma AstraZeneca has reached a drug pricing deal with the Trump administration, agreeing to similar discounts across its portfolio to what Pfizer signed onto last week. Under the deal...
View ArticleMeet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob...
Willkommen, bienvenue, welcome back to another edition of Endpoints Weekly. We’re supposed to get a Nor’easter this weekend on the East Coast after a mostly dry summer. The rain is needed, but...
View Article